Home/Pipeline/IQool™ System

IQool™ System

Post-Cardiac Arrest

MarketedCommercial

Key Facts

Indication
Post-Cardiac Arrest
Phase
Marketed
Status
Commercial
Company

About BrainCool

BrainCool Inc. is an innovative medical device company with a mission to improve patient outcomes in acute neuroscience through targeted temperature management. Its core achievement is the development and commercialization of the IQool™ System, a user-friendly platform designed for rapid induction and control of therapeutic hypothermia. The company's strategy centers on penetrating the large North American neurocritical care market by emphasizing clinical utility, ease of use, and portability over legacy cooling methods. As a publicly traded subsidiary, it leverages its Swedish parent's R&D while executing a focused commercial strategy in the U.S.

View full company profile

About BrainCool

BrainCool Inc. is an innovative medical device company with a mission to improve patient outcomes in acute neuroscience through targeted temperature management. Its core achievement is the development and commercialization of the IQool™ System, a user-friendly platform designed for rapid induction and control of therapeutic hypothermia. The company's strategy centers on penetrating the large North American neurocritical care market by emphasizing clinical utility, ease of use, and portability over legacy cooling methods. As a publicly traded subsidiary, it leverages its Swedish parent's R&D while executing a focused commercial strategy in the U.S.

View full company profile

About BrainCool

BrainCool Inc. is an innovative medical device company with a mission to improve patient outcomes in acute neuroscience through targeted temperature management. Its core achievement is the development and commercialization of the IQool™ System, a user-friendly platform designed for rapid induction and control of therapeutic hypothermia. The company's strategy centers on penetrating the large North American neurocritical care market by emphasizing clinical utility, ease of use, and portability over legacy cooling methods. As a publicly traded subsidiary, it leverages its Swedish parent's R&D while executing a focused commercial strategy in the U.S.

View full company profile

Therapeutic Areas